ELEster Licastro

Ester Licastro

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ester Licastro has a total of 67 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Time matters: Circadian effects on stroke pathophysiology

    by Ester Licastro, Rohan Mahesh Patil, Yasin Eshraghi, Alicia Garcia-Culebras, Emiri T Mandeville, Lluis Alzamora Llull, Wenlu Li, Ignacio Lizasoain, Elga Esposito, Maria Angeles Moro, et al.

    In the last three decades, a huge amount of data and number of reports have proved that ischemic brain damage develops differently based on the time of the day at which it occurs. Differences in circadian rhythms between nocturnal rodent models and diurnal humans may explain the lost in translation crisis experienced in the stroke field. To clarify aspects related to circadian rhythm in stroke and to maximize the translatability of preclinical studies in the attempt to identify new promising therapeutic strategies in stroke, changes in biomarkers and systemic biology have been studied after stroke induction in mice. Circadian rhythms influence the metabolic response to stroke in the brain and in the peripheral blood and muscles, with greater efficacy observed during the rodent inactive phase. In the present review article, we intend to summarize the main findings recently published in the field with the attempt to underline the importance of studying the circadian timing in stroke research in order to improve the translation of brain protective strategies from animals to humans.

  • Timing Matters: How Daily Rhythms Affect Remote Ischemic Postconditioning Therapy for Stroke

    by Ester Licastro, Viviana Viscardi, Ornella Cuomo, Rohan Mahesh Patil, Kazuhide Hayakawa, Eng H. Lo, Giuseppe Pignataro, Elga Esposito

    BACKGROUND: Despite promising preclinical results, remote limb ischemic postconditioning efficacy in human stroke treatment remains unclear, with mixed clinical trial outcomes. A potential reason for translational difficulties could be differences in circadian rhythms between nocturnal rodent models and diurnal humans. METHODS: Male C57BL/6J mice were subjected to transient focal cerebral ischemia and then exposed to remote postconditioning during their active or inactive phase and euthanized at 24 hours and 3 days. Infarct volumes were measured using tetrazolium staining. Behavioral outcomes were assessed using the modified Neurological Severity Score, foot-fault test, and adhesive removal test. Brain (striatum ipsilateral) protein levels of PER2 (period circadian regulator 2) and nNOS (neuronal NO synthase) were analyzed by Western blot at 24 hours and 3 days postischemia. 7-nitroindazole, an nNOS inhibitor, was injected intracerebroventricular, and PER2 protein levels were measured during the inactive phase. RESULTS: Remote postconditioning reduced infarct volumes and improved behavioral outcomes in mice when strokes occurred during the inactive phase (Zeitgeber 1–5) but had no effect during the active phase (Zeitgeber 13–17) 24 hours and 3 days postischemia. During the inactive phase, remote postconditioning reduced PER2 expression and increased nNOS levels; however, these changes were not observed during the active phase. Treatment with the nNOS inhibitor abolished the difference in PER2 expression between control and remote postconditioning groups during the inactive phase. CONCLUSIONS: Circadian rhythms influence the neuroprotective effects of remote postconditioning, with greater efficacy observed during the rodent inactive phase up to 3 days. The underlying mechanism may involve nNOS-dependent regulation of PER2 during remote limb ischemic postconditioning. These findings suggest that circadian timing should be considered in remote postconditioning stroke research to improve the translation of neuroprotective strategies from animals to humans.


  • Open Access

    Novel 1,4-benzothiazepin-2-one modulators of NCX3 as a promising strategy for neuroprotection in cerebral ischemia

    by Antonia Scognamiglio, Angela Corvino, Agata ZięBa, Agnieszka A. Kaczor, Agnese Secondo, Anna Pannaccione, Tuomo Laitinen, Paolo Luciano, Rocco Vitalone, Ornella Cuomo, et al.

  • Therapeutic mitochondria treatment amplifies macrophage-mediated phagocytosis and recycling exocytosis

    by Masayoshi Tanaka, Shin Ishikane, Dong Bin Back, Ester Licastro, Fang Zhang, Ji Hyun Park, Elga Esposito, Giuseppe Pignataro, Takafumi Nakano, Yoshihiko Nakamura, et al.

    Therapeutic administration of mitochondria has been increasingly explored. However, how these administered mitochondria impact immune response remains to be fully addressed. In this proof-of-concept study, we show that extracellularly added mitochondria to cultured peritoneal macrophages increase phagocytosis and recycling exocytosis that amplifies neuroplasticity mediated by recycled mitochondria transfer. Macrophage activation markers such as Nos2 , Arg1 , and Cd163 were unchanged at 3 h post-treatment with mitochondria, but whole mitochondria or delivery of mRNAs extracted from whole mitochondria appeared to increase SQSTM1 protein and activate Nrf2-mediated phagocytosis in macrophages, whereas mitochondria treatment did not change the ability of phagocytosis in cultured microglia or astrocytes. Notably, the once engulfed mitochondria in macrophages appear to be released via Rab27a-mediated recycling pathway that were favorably incorporated in mechanically damaged neurons compared with healthy neurons, resulting in accelerating neurite extension in damaged neurons in a direct co-culture model. Altogether, these findings uncover unappreciated mechanisms that mitochondria-treated macrophages upregulate phagocytosis and recycling exocytosis, implicating that engineering mitochondria delivery to macrophages is a new therapeutic intervention to promote neurorecovery in CNS disorders.


  • Open Access

    The Antidepressant Drug Amitriptyline Affects Human SH-SY5Y Neuroblastoma Cell Proliferation and Modulates Autophagy

    by Annagrazia Adornetto, Maria Luisa Laganà, Andrea Satriano, Ester Licastro, Maria Tiziana Corasaniti, Giacinto Bagetta, Rossella Russo

    Amitriptyline is a tricyclic antidepressant commonly used for depressive disorders and is prescribed off-label for several neurological conditions like neuropathic pain, migraines and anxiety. Besides their action on the reuptake of monoaminergic neurotransmitters, tricyclic antidepressants interact with several additional targets that may contribute to either therapeutic or adverse effects. Here, we investigated the effects of amitriptyline on proliferation and autophagy (i.e., an evolutionarily conserved catabolic pathway responsible for the degradation and recycling of cytoplasmic material) in human SH-SY5Y neuroblastoma cell cultures. The dose and time-dependent upregulation of the autophagy marker LC3II and the autophagy receptor p62, with the accumulation of LAMP1 positive compartments, were observed in SH-SY5Y cells exposed to the amitriptyline. These effects were accompanied by reduced cell viability and decreased clonogenic capacity, without a significant induction of apoptosis. Decrease viability and clonogenic activity were still observed in autophagy deficient Atg5−/− MEF and following pre-treatment of SH-SY5Y culture with the autophagy inhibitor chloroquine, suggesting that they were independent from autophagy modulation. Our findings demonstrate that amitriptyline acts on pathways crucial for cell and tissue homeostasis (i.e., autophagy and proliferation) and pose the basis for further studies on the potential therapeutic application of amitriptyline, as well as the consequences of its use for long-term treatments.


  • Top Cited Papers
    Open Access

    Glymphatic and lymphatic communication with systemic responses during physiological and pathological conditions in the central nervous system

    by Ester Licastro, Giuseppe Pignataro, Jeffrey J. Iliff, Yanxiao Xiang, Eng H. Lo, Kazuhide Hayakawa, Elga Esposito

    Crosstalk between central nervous system (CNS) and systemic responses is important in many pathological conditions, including stroke, neurodegeneration, schizophrenia, epilepsy, etc. Accumulating evidence suggest that signals for central-systemic crosstalk may utilize glymphatic and lymphatic pathways. The glymphatic system is functionally connected to the meningeal lymphatic system, and together these pathways may be involved in the distribution of soluble proteins and clearance of metabolites and waste products from the CNS. Lymphatic vessels in the dura and meninges transport cerebrospinal fluid, in part collected from the glymphatic system, to the cervical lymph nodes, where solutes coming from the brain (i.e., VEGFC, oligomeric α-syn, β-amyloid) might activate a systemic inflammatory response. There is also an element of time since the immune system is strongly regulated by circadian rhythms, and both glymphatic and lymphatic dynamics have been shown to change during the day and night. Understanding the mechanisms regulating the brain-cervical lymph node (CLN) signaling and how it might be affected by diurnal or circadian rhythms is fundamental to find specific targets and timing for therapeutic interventions.


  • Open Access

    O-GlcNAcylation is essential for therapeutic mitochondrial transplantation

    by Ji Hyun Park, Masayoshi Tanaka, Takafumi Nakano, Ester Licastro, Yoshihiko Nakamura, Wenlu Li, Elga Esposito, Emiri T. Mandeville, Sherry Hsiang-Yi Chou, MingMing Ning, et al.

    Background: Transplantation of mitochondria is increasingly explored as a novel therapy in central nervous system (CNS) injury and disease. However, there are limitations in safety and efficacy because mitochondria are vulnerable in extracellular environments and damaged mitochondria can induce unfavorable danger signals. Methods: Mitochondrial O-GlcNAc-modification was amplified by recombinant O-GlcNAc transferase (OGT) and UDP-GlcNAc. O-GlcNAcylated mitochondrial proteins were identified by mass spectrometry and the antiglycation ability of O-GlcNAcylated DJ1 was determined by loss-of-function via mutagenesis. Therapeutic efficacy of O-GlcNAcylated mitochondria was assessed in a mouse model of transient focal cerebral ischemia-reperfusion. To explore translational potential, we evaluated O-GlcNAcylated DJ1 in CSF collected from patients with subarachnoid hemorrhagic stroke (SAH). Results: We show that isolated mitochondria are susceptible to advanced glycation end product (AGE) modification, and these glycated mitochondria induce the receptor for advanced glycation end product (RAGE)-mediated autophagy and oxidative stress when transferred into neurons. However, modifying mitochondria with O-GlcNAcylation counteracts glycation, diminishes RAGE-mediated effects, and improves viability of mitochondria recipient neurons. In a mouse model of stroke, treatment with extracellular mitochondria modified by O-GlcNAcylation reduces neuronal injury and improves neurologic deficits. In cerebrospinal fluid (CSF) samples from SAH patients, levels of O-GlcNAcylation in extracellular mitochondria correlate with better clinical outcomes. Conclusions: These findings suggest that AGE-modification in extracellular mitochondria may induce danger signals, but O-GlcNAcylation can prevent glycation and improve the therapeutic efficacy of transplanted mitochondria in the CNS.


  • Open Access

    Neuroprotective Effect of a Nutritional Supplement Containing Spearmint Extract, Forskolin, Homotaurine and Group B Vitamins in a Mouse Model of Transient Ocular Hypertension

    by Andrea Satriano, Maria Luisa Laganà, Ester Licastro, Carlo Nucci, Giacinto Bagetta, Rossella Russo, Annagrazia Adornetto

    Glaucoma is one of the most common sight-threatening eye disorders and one of the main causes of irreversible blindness worldwide. The current therapies focusing on reducing intraocular pressure (IOP) are often insufficient to prevent the progression of the disease, so the therapeutic management of glaucoma remains a challenge. The aim of this study was to evaluate the neuroprotective, IOP-lowering independent effects of a nutritional supplement containing forskolin, homotaurine, spearmint extract and vitamins of the B group in a model of acute glaucoma developed in mice. Glaucoma was induced in adult wild-type C57BL/6J mice by transient elevation of IOP. The dietary supplement, branded as Gangliomix® (125 mg/kg/day), was administered by oral gavage for 17 days and ocular hypertension was induced on the 10th day of treatment. A histological analysis of the retinas was performed and RGC survival was evaluated with fluorogold labeling and Brn3a immunostaining on wholemount and retinal sections. Expression of alpha-spectrin, caspase-3, PARP-1 and GFAP was studied with western blotting or immunofluorescence. A significant increase in RGC survival was reported in the retina of mice treated with the dietary supplement as compared to vehicle-treated animals. The observed neuroprotection was associated with a calpain activity decrease, reduction in caspase-3 and PARP-1 activation, and prevention of GFAP upregulation. These effects were independent from the hypotensive effects of the supplement. Altogether, our data suggest that the dietary supplementation with forskolin, homotaurine, spearmint extract and vitamins of the B group supports RGC survival and may offer beneficial effects in glaucoma patients in combination with the currently used IOP-lowering therapy.


  • Open Access

    Neuroprotective and Anti-Inflammatory Effects of a Hydrophilic Saffron Extract in a Model of Glaucoma

    by Jose A. Fernández-Albarral, Ana I. Ramírez, Rosa de Hoz, Nerea López-Villarín, Elena Salobrar-García, Inés López-Cuenca, Ester Licastro, Antonio M. Inarejos-García, Paula Almodóvar, Maria D. Pinazo-Durán, et al.

    Glaucoma is a neurodegenerative disease characterized by the loss of retinal ganglion cells (RGCs). An increase in the intraocular pressure is the principal risk factor for such loss, but controlling this pressure does not always prevent glaucomatous damage. Activation of immune cells resident in the retina (microglia) may contribute to RGC death. Thus, a substance with anti-inflammatory activity may protect against RGC degeneration. This study investigated the neuroprotective and anti-inflammatory effects of a hydrophilic saffron extract standardized to 3% crocin content in a mouse model of unilateral, laser-induced ocular hypertension (OHT). Treatment with saffron extract decreased microglion numbers and morphological signs of their activation, including soma size and process retraction, both in OHT and in contralateral eyes. Saffron extract treatment also partially reversed OHT-induced down-regulation of P2RY12. In addition, the extract prevented retinal ganglion cell death in OHT eyes. Oral administration of saffron extract was able to decrease the neuroinflammation associated with increased intraocular pressure, preventing retinal ganglion cell death. Our findings indicate that saffron extract may exert a protective effect in glaucomatous pathology.